South Korea · Delayed Price · Currency is KRW QuadMedicine Statistics
Total Valuation
QuadMedicine has a market cap or net worth of KRW 56.20 billion. The enterprise value is 46.95 billion.
| Market Cap | 56.20B |
| Enterprise Value | 46.95B |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
QuadMedicine has 11.48 million shares outstanding. The number of shares has increased by 17.91% in one year.
| Current Share Class | 11.48M |
| Shares Outstanding | 11.48M |
| Shares Change (YoY) | +17.91% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 26.24% |
| Owned by Institutions (%) | 4.32% |
| Float | 7.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.87 |
| PB Ratio | 2.29 |
| P/TBV Ratio | 2.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.34.
| Current Ratio | 1.58 |
| Quick Ratio | 1.50 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.86 |
| Interest Coverage | -28.69 |
Financial Efficiency
Return on equity (ROE) is -60.26% and return on invested capital (ROIC) is -25.00%.
| Return on Equity (ROE) | -60.26% |
| Return on Assets (ROA) | -15.67% |
| Return on Invested Capital (ROIC) | -25.00% |
| Return on Capital Employed (ROCE) | -29.34% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 5,614.30 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 36.16 |
| Average Volume (20 Days) | 32,629 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, QuadMedicine had revenue of KRW 7.14 billion and -10.11 billion in losses. Loss per share was -948.83.
| Revenue | 7.14B |
| Gross Profit | 7.14B |
| Operating Income | -9.85B |
| Pretax Income | -10.11B |
| Net Income | -10.11B |
| EBITDA | -6.33B |
| EBIT | -9.85B |
| Loss Per Share | -948.83 |
Balance Sheet
The company has 17.67 billion in cash and 8.41 billion in debt, with a net cash position of 9.26 billion or 806.40 per share.
| Cash & Cash Equivalents | 17.67B |
| Total Debt | 8.41B |
| Net Cash | 9.26B |
| Net Cash Per Share | 806.40 |
| Equity (Book Value) | 24.55B |
| Book Value Per Share | 2,142.49 |
| Working Capital | 8.84B |
Cash Flow
In the last 12 months, operating cash flow was -5.75 billion and capital expenditures -3.98 billion, giving a free cash flow of -9.73 billion.
| Operating Cash Flow | -5.75B |
| Capital Expenditures | -3.98B |
| Depreciation & Amortization | 3.52B |
| Net Borrowing | 503.39M |
| Free Cash Flow | -9.73B |
| FCF Per Share | -847.00 |
Margins
Gross margin is 100.00%, with operating and profit margins of -137.93% and -141.51%.
| Gross Margin | 100.00% |
| Operating Margin | -137.93% |
| Pretax Margin | -141.51% |
| Profit Margin | -141.51% |
| EBITDA Margin | -88.64% |
| EBIT Margin | -137.93% |
| FCF Margin | n/a |
Dividends & Yields
QuadMedicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.91% |
| Shareholder Yield | -17.91% |
| Earnings Yield | -17.98% |
| FCF Yield | -17.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
QuadMedicine has an Altman Z-Score of 1.93 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.93 |
| Piotroski F-Score | 1 |